CRISPR Activation Enhances In Vitro Potency of AAV Vectors Driven by Tissue-Specific Promoters
Validation of gene transfer vectors containing tissue-specific promoters in cell-based functional assays poses a formidable challenge for gene therapy product development. Here, we describe a novel approach based on CRISPR/dCas9 transcriptional activation to achieve robust transgene expression from...
Main Authors: | Devin S. McDougald, Thu T. Duong, Katherine C. Palozola, Anson Marsh, Tyler E. Papp, Jason A. Mills, Shangzhen Zhou, Jean Bennett |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-06-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050119300312 |
Similar Items
-
AAV2.7m8 is a powerful viral vector for inner ear gene therapy
by: Kevin Isgrig, et al.
Published: (2019-01-01) -
Comparative AAV-eGFP Transgene Expression Using Vector Serotypes 1–9, 7m8, and 8b in Human Pluripotent Stem Cells, RPEs, and Human and Rat Cortical Neurons
by: Thu T. Duong, et al.
Published: (2019-01-01) -
The use of matrix attachment regions to enhance the in-vivo potency of rAAV vectors
by: Hanley, J. E.
Published: (2014) -
High levels of AAV vector integration into CRISPR-induced DNA breaks
by: Killian S. Hanlon, et al.
Published: (2019-09-01) -
Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors
by: Chen Ling, et al.
Published: (2016-01-01)